BridgeBio Pharma BBIO Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $170.49M-75.0% | $683.24M+81.7% | $375.94M-0.2% | $376.69M-4.3% | ||
| $17.36M— | $0— | $0-100% | $51.58M-86.9% | ||
| $139.44M+2,853% | $4.72M+170% | $1.75M+146% | -$3.79M— | ||
| $73.51M— | $0— | $0— | —— | ||
| $797.75M+10.7% | $720.69M+50.9% | $477.59M-13.0% | $548.85M-38.3% | ||
| $5.37M-23.5% | $7.01M-40.7% | $11.82M-18.9% | $14.57M-51.5% | ||
| $28.08M+17.3% | $23.93M-9.1% | $26.32M-8.3% | $28.71M-36.1% | ||
| $936.03M+1.8% | $919.34M+68.3% | $546.38M-12.3% | $623.04M-38.5% | ||
| $108.59M+137% | $45.84M+98.6% | $23.08M-43.2% | $40.62M-28.2% | ||
| $7.19M-50.8% | $14.6M+292% | $3.73M-54.3% | $8.16M— | ||
| —— | —— | —— | —— | ||
| $287.97M+86.5% | $154.4M+7.3% | $143.84M+18.5% | $121.43M-10.1% | ||
| —— | $437.34M-2.0% | $446.45M+3.6% | $430.99M+0.1% | ||
| $3.01B+26.7% | $2.38B+25.8% | $1.89B+1.1% | $1.87B-0.6% | ||
| 500M+255,002% | 196K+8.3% | 181K+15.3% | 157K+1.9% | ||
| -$3.82B-23.4% | -$3.1B-20.9% | -$2.56B-33.5% | -$1.92B-33.5% | ||
| -$2.09B-42.1% | -$1.47B-8.4% | -$1.35B-7.9% | -$1.25B-44.1% | ||
| $936.03M+1.8% | $919.34M+68.3% | $546.38M-12.3% | $623.04M-38.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are BridgeBio Pharma's total assets?
- BridgeBio Pharma (BBIO) holds $1.4B in total assets, up 55.5% year over year.
- How much debt does BridgeBio Pharma have?
- BridgeBio Pharma carries $3.3B in total debt against -$2.3B of shareholders' equity, a debt-to-equity ratio of 1.97.
- How much cash does BridgeBio Pharma have?
- BridgeBio Pharma holds $882.0M in cash and equivalents.
- Can BridgeBio Pharma cover its short-term obligations?
- Its current ratio is 1.52 — current assets exceed current liabilities.
- Where does BridgeBio Pharma's balance sheet data come from?
- Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
